$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Injection Pen (Disposable, Reusable Pens) Market - Global Forecast to 2026 with Novo Nordisk, Eli Lilly and Co, Sanofi, and Novartis Dominating - ResearchAndMarkets.com
05:44pm, Thursday, 16'th Dec 2021 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Injection Pen Market by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region - Global Forecast to 2026" report has been added to ResearchAndMarkets.com''s offering. The global injection pens market is projected to reach USD 53.3 billion by 2026 from USD 37.6 billion in 2021, at a CAGR of 7.2%. Growing prevalence of chron
Eukles Asset Management Grows Position in Novo Nordisk A/S (NYSE:NVO)
01:54pm, Thursday, 16'th Dec 2021 Transcript Daily
Eukles Asset Management raised its position in Novo Nordisk A/S (NYSE:NVO) by 3.6% during the third quarter, HoldingsChannel.com reports. The firm owned 28,943 shares of the companys stock after buying an additional 995 shares during the quarter. Novo Nordisk A/S comprises 1.5% of Eukles Asset Managements investment portfolio, making the stock its 25th biggest position. []
Novo Nordisk Saudi honored as the top workplace for Women in 2021
12:16pm, Thursday, 16'th Dec 2021 PR Newswire
RIYADH, Saudia Arabia, Dec. 16, 2021 /PRNewswire/ -- Novo Nordisk Saudi, an affiliate of the global healthcare company with more than 90 years of innovation and leadership in diabetes care, has been recently recognized as the top workplace for women in the Kingdom for the second
Best Places To Work: The Top 7 Best Companies to Work for in Saudi 2021 revealed
02:34pm, Wednesday, 15'th Dec 2021 FinanzNachrichten
RIYADH, Saudi Arabia, Dec. 15, 2021 /PRNewswire/ -- Novo Nordisk Saudi, Manga Productions, Foodics, Tamkeen Technologies, Roshn, International Maritime Industries and Saudi Arabian Packaging Indus
The Top 7 Best Companies to Work for in Saudi 2021 revealed
02:26pm, Wednesday, 15'th Dec 2021 PR Newswire
RIYADH, Saudi Arabia, Dec. 15, 2021 /PRNewswire/ -- Novo Nordisk Saudi, Manga Productions, Foodics, Tamkeen Technologies, Roshn, International Maritime Industries and Saudi Arabian Packaging Industry are recognized as the top 7 best places to work in Saudi Arabia for 2021, according to…
New once-weekly Ozempic for treatment of type 2 diabetes now available in Egypt
12:52pm, Tuesday, 14'th Dec 2021 Daily News Egypt
Novo Nordisk, a global pharmaceutical company specialized in diabetes, announced that once-weekly Ozempic for the treatment of type 2 diabetes, is now available in Egypt. Alongside diet and exercise, Ozempic can either be used alone or in addition to other products for diabetes management. The post New once-weekly Ozempic for treatment of type 2 diabetes now available in Egypt appeared first on Daily News Egypt .
Women''S Health Market is a completely ready-to-refer market research presentation that offers vital information, such as market share, market size, CAGR, and the directly impacting factors. The updated research report presents actionable insights to the market vendors involved and other
Novo Nordisk to invest in new production facilities at Danish plant
09:41am, Tuesday, 14'th Dec 2021 Pharmaceutical Business Review
Novo Nordisk has announced plans to make more than $2.58bn (DKK17bn) investment to expand its manufacturing facilities in Kalundborg, Denmark. The company plans to construct three new manufacturing The post Novo Nordisk to invest in new production facilities at Danish plant appeared first on Pharmaceutical Business review .
Brokerages Set Novo Nordisk A/S (NYSE:NVO) Target Price at $341.50
12:06pm, Monday, 13'th Dec 2021 Transcript Daily
Novo Nordisk A/S (NYSE:NVO) has received an average recommendation of “Hold” from the thirteen brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective […]
Fisher Asset Management LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)
04:48pm, Sunday, 12'th Dec 2021 Transcript Daily
Fisher Asset Management LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,175,539 shares of the companys stock after buying an additional 93,552 shares during the quarter. Novo Nordisk A/S comprises 1.0% []
Crossmark Global Holdings Inc. Grows Stake in Novo Nordisk A/S (NYSE:NVO)
12:58pm, Saturday, 11'th Dec 2021 Dakota Financial News
Crossmark Global Holdings Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO) by 0.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,805 shares of the companys stock after buying an additional 110 shares during the period. Crossmark Global Holdings []
Drugmakers aim big price hikes at U.S. patients -congressional report
01:36pm, Friday, 10'th Dec 2021 Reuters
Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on Friday by the House Oversight Committee that highlighted Eli Lilly and Co , Novo Nordisk and Sanofi , which control the market for insulin.
JJJ Advisors Inc. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)
10:52am, Friday, 10'th Dec 2021 Dakota Financial News
JJJ Advisors Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 7.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,632 shares of the companys stock after acquiring an additional 183 shares during the quarter. JJJ Advisors Inc.s holdings []
According to the new market research report "Injection Pen Market by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region - Global Forecast to 2026",
FY2022 EPS Estimates for Novo Nordisk A/S (NYSE:NVO) Reduced by Analyst
07:32am, Friday, 10'th Dec 2021 Dakota Financial News
Novo Nordisk A/S (NYSE:NVO) Stock analysts at Jefferies Financial Group cut their FY2022 earnings estimates for shares of Novo Nordisk A/S in a research note issued to investors on Tuesday, December 7th. Jefferies Financial Group analyst P. Welford now expects that the company will earn $3.66 per share for the year, down from their []
Sign In
Buy NVO